Incannex Healthcare: Pioneering Combination Medicines and Psychedelic Therapies
32 min
Incannex Healthcare: Pioneering Combination Medicines and Psychedelic Therapies
Blunt Business
0:00--:--
Blunt Business speaks with Joel Latham, CEO of Incannex Healthcare (NASDAQ: IXHL), a clinical-stage biopharmaceutical company pioneering the use of proprietary combination medicines. Latham breaks down their strategy of fusing synthetic cannabinoids and well-characterized active drug components to target chronic conditions with significant unmet needs, emphasizing a robust intellectual property position and synergistic drug action.